ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
A novel set of compounds with antimicrobial properties has been discovered in the fight against Helicobacter pylori, a bacterium that has infected more than 1 billion people worldwide and causes gastrointestinal troubles that can lead to cancer (ACS Chem. Biol., DOI: 10.1021/cb900166q). Treatment with conventional broad-spectrum antibiotics such as amoxicillin and clarithromycin is effective, but H. pylori is becoming resistant to these drugs. By high-throughput screening of a library of 10,000 compounds, Javier Sancho of Spain’s University of Zaragoza and colleagues identified four compounds that inhibit flavodoxin, a protein involved in an essential H. pylori metabolic pathway. Three of the compounds, including the two shown, demonstrate selective bactericidal activity against H. pylori and have no apparent toxic effects in mice. The researchers note that these compounds represent promising leads for narrow-spectrum antibiotics to treat H. pylori infections.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X